Background and Methods: We previously reported the development of site-directed monoclonal antibodies able to inhibit the initiation of the amyloid precursor protein (APP) processing site, named ‘blocking β site 1' (BBS1). The beneficial effect of intracerebroventricular administration of these antibodies in the triple transgenic mouse model of Alzheimer's disease (AD) showed improvement in cognitive functions and reduction in tau and amyloid pathology. Amyloid-β may not be the only active component of AD neurotoxicity and may involve other proteolytic APP fragments such as the APP intracellular domain, proposed to work as a transcription factor involved in the regulation of p53 and glycogen synthase kinase 3β (GSK3β) as well as affecting several physiological processes contributing to AD pathology. Results: We show that inhibition of the β-secretase cleavage site via site-directed antibodies resulted in a major reduction in phosphorylated GSK3β levels, which is the active form of GSK3β, as well as in p53 levels. Conclusion: A therapy that is capable of reducing not only the direct hallmarks of AD but also the components that lead to neuronal apoptosis might have neuroprotective potential in AD treatment.

1.
Arbel M, Yacoby I, Solomon B: Inhibition of amyloid precursor protein processing by beta-secretase through site-directed antibodies. Proc Natl Acad Sci USA 2005;102:7718-7723.
2.
Rakover I, Arbel M, Solomon B: Immunotherapy against APP beta-secretase cleavage site improves cognitive function and reduces neuroinflammation in Tg2576 mice without a significant effect on brain Abeta levels. Neurodegener Dis 2007;4:392-402.
3.
Arbel-Ornath M, Becker M, Rabinovich-Toidman P, Gartner M, Solomon B: Immunomodulation of AβPP processing alleviates amyloid-β-related pathology in Alzheimer's disease transgenic mice. J Alzheimers Dis 2010;22:469-482.
4.
Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM: Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 2003;31:39:409-421.
5.
Rabinovich-Nikitin I, Rakover IS, Becker M, Solomon B: Beneficial effect of antibodies against β-secretase cleavage site of APP on Alzheimer's-like pathology in triple-transgenic mice. PLoS One 2012;7:e46650.
6.
Pimplikar SW, Suryanarayana A: Detection of APP intracellular domain in brain tissue. Methods Mol Biol 2011;670:85-91.
7.
Yoon SY, Choi JE, Yoon JH, Huh JW, Kim DH: BACE inhibitor reduces APP-beta-C-terminal fragment accumulation in axonal swellings of okadaic acid-induced neurodegeneration. Neurobiol Dis 2006;22:435-444.
8.
Kim HS, Kim EM, Lee JP, Park CH, Kim S, Seo JH, Chang KA, Yu E, Jeong SJ, Chong YH, Suh YH: C-terminal fragments of amyloid precursor protein exert neurotoxicity by inducing glycogen synthase kinase-3beta expression. FASEB J 2003;17:1951-1953.
9.
Alves da Costa C, Sunyach C, Pardossi-Piquard R, Sévalle J, Vincent B, Boyer N, Kawarai T, Girardot N, St George-Hyslop P, Checler F: Presenilin-dependent gamma-secretase-mediated control of p53-associated cell death in Alzheimer's disease. J Neurosci 2006;26:6377-6385.
10.
Stanga S, Lanni C, Govoni S, Uberti D, D'Orazi G, Racchi M: Unfolded p53 in the pathogenesis of Alzheimer's disease: is HIPK2 the link? Aging (Albany NY) 2010;2:545-554.
11.
Xu X, Yang D, Wyss-Coray T, Yan J, Gan L, Sun Y, Mucke L: Wild-type but not Alzheimer-mutant amyloid precursor protein confers resistance against p53-mediated apoptosis. Proc Natl Acad Sci USA 1999;96:7547-7552.
12.
Ozaki T, Li Y, Kikuchi H, Tomita T, Iwatsubo T, Nakagawara A: The intracellular domain of the amyloid precursor protein (AICD) enhances the p53-mediated apoptosis. Biochem Biophys Res Commun 2006;351:57-63.
13.
Watcharasit P, Bijur GN, Song L, Zhu J, Chen X, Jope RS: Glycogen synthase kinase-3beta (GSK3beta) binds to and promotes the actions of p53. J Biol Chem 2002;278:48872-48879.
14.
Checler F, Dunys J, Pardossi-Piquard R, Alves da Costa C: p53 is regulated by and regulates members of the gamma-secretase complex. Neurodegener Dis 2010;7:50-55.
15.
Pardossi-Piquard R, Checler F: The physiology of the β-amyloid precursor protein intracellular domain AICD. J Neurochem 2012;120(suppl 1):109-124.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.